Warhound launches $200M venture to clone elite military dogs

Warhound, a new startup backed by Ben Lamm and Palmer Luckey, has raised $200 million to genetically engineer and clone dogs for the US military. The company plans to use cell samples from high-performing canines to reduce common health issues while preparing them for active duty. The first batch of these modified animals is expected to be born in early 2027.

The initial group of donor dogs consists primarily of Belgian Malinois, with some Labradors and German Shepherds mixed in. These animals previously served in military, police, or first responder roles across the United States. Lamm confirmed to Wired that scientists at Colossal Biosciences have already begun editing the genes of these cell samples.

The primary goal of the genetic modifications is to lower the risk of hip dysplasia and specific cancers that frequently affect these breeds. Lamm indicated to TechCrunch that future edits could improve physical traits, such as speed, agility, and olfactory sensitivity, although the current focus remains on health.

Luckey, founder of Anduril and Oculus VR, is a partner in the venture but does not hold an ownership stake in the company. Lamm’s firm, Colossal Biosciences, holds equity, and Lamm serves on the board. David Spirk, formerly of Palantir, leads the company as chief executive. This structure separates the biological work from the hardware development.

Anduril’s contribution is limited to equipment and software. The firm will design protective gear for the dogs, including goggles, vests, and body armor. Warhound is not currently planning to create cyborgs, focusing instead on enhancing the biological resilience of the animals and protecting them with technology they can wear.

The cloned dogs will be trained for standard working tasks, such as bomb detection and search-and-rescue operations. The project represents a shift toward using genetic tools to solve longstanding problems in service animal health and durability.